Key facts
- This page summarizes Jeffrey Allen Morris's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Aug 2023, 19:07.
Jeffrey Allen Morris - 11 Aug 2023 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PVCT
- Reported as of
- 11 Aug 2023
- Net transaction value
- +$700,000
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2023, 19:07:30 UTC
- Prior SEC filing
- 09 May 2023
- Next SEC filing
- 14 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Allen Morris
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Allen Morris filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 14 Aug 2023.
Change
- Previous filing in this sequence was filed on 09 May 2023.
- Current net transaction value: +$700,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PVCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,000,000
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
PVCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,500,000
- Date
- 11 Aug 2023
- Ownership
- By IRA
- Footnotes
- F2
PVCT
holding
Series D-1 Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,995,747
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVCT
transaction
Derivative
8% Secured Convertible Promissory Note
Award
- Transaction value
- $700,000
- Shares
- Change %
- Price
- Shares after
- 244,584
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Series D-1 Convertible Preferred Stock
- Underlying amount
- 244,584
- Exercise price
- $2.86
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
Footnote F2
The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
Footnote F3
The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock.
Footnote F4
The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
Footnote F5
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").